{"paper_id": "5e303814ad0fd63c593a14c4c27901e932cff53e", "metadata": {"title": "Epigenetic susceptibility to severe respiratory viral infections: pathogenic and therapeutic implications: a narrative review", "authors": [{"first": "Ettore", "middle": [], "last": "Crimi", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Central Florida", "location": {"settlement": "Orlando", "region": "FL", "country": "USA"}}, "email": ""}, {"first": "Giuditta", "middle": [], "last": "Benincasa", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Campania Luigi Vanvitelli", "location": {"settlement": "Naples", "country": "Italy"}}, "email": ""}, {"first": "Neisaliz", "middle": [], "last": "Figueroa-Marrero", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Central Florida", "location": {"settlement": "Orlando", "region": "FL", "country": "USA"}}, "email": ""}, {"first": "Massimiliano", "middle": [], "last": "Galdiero", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Campania Luigi Vanvitelli", "location": {"settlement": "Naples", "country": "Italy"}}, "email": ""}, {"first": "Claudio", "middle": [], "last": "Napoli", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Campania Luigi Vanvitelli", "location": {"settlement": "Naples", "country": "Italy"}}, "email": ""}]}, "abstract": [{"text": "The emergence of highly pathogenic strains of influenza virus and coronavirus (CoV) has been responsible for large epidemic and pandemic outbreaks characterised by severe pulmonary illness associated with high morbidity and mortality. One major challenge for critical care is to stratify and minimise the risk of multi-organ failure during the stay in the intensive care unit (ICU). Epigenetic-sensitive mechanisms, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) methylation, histone modifications, and non-coding RNAs may lead to perturbations of the host immunerelated transcriptional programmes by regulating chromatin structure and gene expression patterns. Viruses causing severe pulmonary illness can use epigenetic-regulated mechanisms during hostepathogen interaction to interfere with innate and adaptive immunity, adequacy of inflammatory response, and overall outcome of viral infections. For example, Middle East respiratory syndrome-CoV and H5N1 can affect host antigen presentation through DNA methylation and histone modifications. The same mechanisms would presumably occur in patients with coronavirus disease 2019, in which tocilizumab may epigenetically reduce microvascular damage. Targeting epigenetic pathways by immune modulators (e.g. tocilizumab) or repurposed drugs (e.g. statins) may provide novel therapeutic opportunities to control viralehost interaction during critical illness. In this article, we provide an update on epigenetic-sensitive mechanisms and repurposed drugs interfering with epigenetic pathways which may be clinically suitable for risk stratification and beneficial for treatment of patients affected by severe viral respiratory infections.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "The authors reviewed the literature and ongoing clinical trials, and show that epigenetic biomarkers may stratify the risk of severe respiratory infection. As deoxyribonucleic acid methylation can be reversed, at least partially, some drugs (curcumin, apabetalone, and repurposed drugs such as statins and tocilizumab) may contribute to better treatment of such patients by interfering with epigenetic pathways.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "Over the past two decades, we have experienced the emergence of newly recognised highly pathogenic strains of influenza virus (i.e. influenza A virus subtype H1N1 or swine", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "influenza, and influenza A virus subtype H5N1 or avian influenza) and coronavirus (CoV) (i.e. severe acute respiratory syndrome [SARS]-CoV, Middle East respiratory syndrome [MERS]-CoV, and SARS-CoV-2) responsible for pandemic infections associated with high morbidity and mortality. 1e5 These viruses may cause a wide spectrum of respiratory manifestations associated with massive inflammatory cell infiltration and proinflammatory cytokine/chemokine release resulting in acute lung injury (ALI); acute respiratory distress syndrome (ARDS); and, ultimately, death from multi-organ failure (MOF). 6e8 Molecular mechanisms regulating virusehost interactions can significantly affect the degree and adequacy of both immune and inflammatory responses influencing clinical outcomes. 9e11 For the critical care physicians, to identify and prevent the occurrence of this exuberant inflammatory response and to stratify the risk of MOF in the intensive care unit (ICU) are still major challenges. 12 Epigenetics may influence host susceptibility to such viral infections. 13 Deoxyribonucleic acid (DNA) methylation, ribonucleic acid (RNA) methylation, histone tail changes, and also non-coding RNAs are heritable and acquired modifications able to alter gene expression at different levels without any changes in the primary DNA sequence. Epigenetic mechanisms, by regulating chromatin structure and gene expression patterns, modulate host immunity and inflammatory response. 14 In critical illness, such epigenetic modifications can promote the release of proinflammatory cytokines and activation of inflammatory cells, responsible for oxidative stress, endothelial dysfunction, apoptosis, and MOF. 15 Epigenetics can also regulate the interaction between host and multidrug-resistant bacteria. 16 The interaction of viruses with host cells can cause perturbations of transcriptional programmes involving such epigenetic mechanisms leading to viral shedding and inadequate immune response. 13 Middle East respiratory syndrome-CoV and H5N1 infections can antagonise the host immune response by modulating antigen presentation through DNA methylation and histone modifications. 17e20 Similar mechanisms would occur during coronavirus disease 2019 . 21, 22 Indeed, advanced bioinformatic tools have predicted the possibility of using microRNAs (miRNAs) to inhibit infections caused by COVID-19, SARS-CoV, and MERS-CoV by inhibiting the translation of viral proteins and viral replication. 21 As some epigenetic changes can be reversed by small agents, known as 'epidrugs', or alternatively, epigenetic pathways can be interfered by immune modulators, they might provide useful drug targets to ameliorate the clinical outcome during viral respiratory infections. 23, 24 Ongoing trials will answer to this possible clinical application. The goal of the review was to provide an appropriate pathogenic scenario in which epigenetic-sensitive mechanisms and epidrugs may be clinically useful to stratify risk and treatment of patients in ICU affected by severe viral respiratory infections.", "cite_spans": [{"start": 283, "end": 286, "text": "1e5", "ref_id": null}, {"start": 778, "end": 782, "text": "9e11", "ref_id": null}, {"start": 989, "end": 991, "text": "12", "ref_id": "BIBREF11"}, {"start": 1064, "end": 1066, "text": "13", "ref_id": null}, {"start": 1468, "end": 1470, "text": "14", "ref_id": "BIBREF12"}, {"start": 1692, "end": 1694, "text": "15", "ref_id": "BIBREF13"}, {"start": 1788, "end": 1790, "text": "16", "ref_id": "BIBREF14"}, {"start": 1983, "end": 1985, "text": "13", "ref_id": null}, {"start": 2240, "end": 2243, "text": "21,", "ref_id": "BIBREF19"}, {"start": 2244, "end": 2246, "text": "22", "ref_id": "BIBREF20"}, {"start": 2479, "end": 2481, "text": "21", "ref_id": "BIBREF19"}, {"start": 2752, "end": 2755, "text": "23,", "ref_id": "BIBREF21"}, {"start": 2756, "end": 2758, "text": "24", "ref_id": "BIBREF22"}], "ref_spans": [], "section": ""}, {"text": "Influenza viruses are enveloped, single-stranded RNA viruses classified into three major serotypes: A, B, and C. Influenza A viruses, the most extensively studied, are further classified based on the different subtypes of the two surface glycoproteins: haemagglutinin (H1eH18) and neuraminidase (N1eN11) which facilitate virus binding to host respiratory epithelial cells via a sialic acid receptor and virions released from cells, respectively. 25 Avian influenza A virus H5N1 26\u00c028 and swine influenza A H1N1 29\u00c034 infections have caused acute respiratory failure secondary to severe pneumonia and ARDS. The highly pathogenic avian influenza A virus H5N1, first described in 1996, caused severe pneumonia with high mortality (more than 60%), secondary to ARDS and MOF. 26e28 Risks factors for severe influenza A H1N1 infection included pregnancy, Table 1 Clinical and immunological features of viral respiratory infections by influenza viruses. 36e44 COPD, chronic obstructive pulmonary disease; CR, conventional radiograph; CT, computed tomography; GGO, ground glass opacity; HF, heart failure; IFNg, interferon g; IL-1 RA, interleukin-1 receptor antagonist protein; IP-10, interferon-g-inducible protein-10; MCP-1, monocyte chemoattractant protein-1; MIP 1-b, macrophage inflammatory protein 1-B; TLR-3, Toll-like receptor Type 3; TNF-a, tumour necrosis factor-alpha. obesity, asthma, and chronic obstructive pulmonary disease (COPD). 29e34 Mitigation of the pathogenicity of the pandemic virus was probably caused by the presence of a cross-reactive cell response against this virus, which was boosted by seasonal vaccination. 35 In Table 1, we summarised clinical and  immunological features of viral respiratory infections by  influenza viruses. 36e44 Coronaviruses Coronaviruses, named after their crown-like structure, are enveloped, positive-sense RNA viruses, containing the largest known genome amongst RNA viruses. The CoV genome encodes for 16 non-structural proteins, which form the viral replicase transcriptase complex, and four essential structural proteins, involved in the host immune response and virion assembly: the spike (S) protein, responsible for receptor binding and viral entry into the host cell; the membrane (M) and envelope (E) proteins, responsible for virus assembly and release; and the nucleocapsid (N) protein, important for RNA synthesis and its final packaging into the viral particles. 45 The genome sequence of SARS-CoV-2 is about 79% identical to the SARS-CoV and 50% to the MERS-CoV. 46 These viruses cause severe respiratory infections (Table 2) . 47e60 Older adults with co-morbidities, especially cardiovascular diseases, diabetes, obesity, renal failure, and COPD, are at higher risk of severe disease. 51, 56 ICU admission for organ support occurs in about 20e30%, 5e36%, and 50e89% of patients infected with SARS-CoV, SARS-CoV-2, and MERS-CoV, respectively. 3,51e53,56 Currently, global public health is facing the COVID-19 pandemic as the third CoV crisis in less than 20 yr (https://www.nih.gov/health-information/coronavirus).", "cite_spans": [{"start": 446, "end": 448, "text": "25", "ref_id": "BIBREF23"}, {"start": 1632, "end": 1634, "text": "35", "ref_id": "BIBREF33"}, {"start": 2427, "end": 2429, "text": "45", "ref_id": "BIBREF43"}, {"start": 2528, "end": 2530, "text": "46", "ref_id": "BIBREF44"}, {"start": 2593, "end": 2598, "text": "47e60", "ref_id": null}, {"start": 2751, "end": 2754, "text": "51,", "ref_id": "BIBREF49"}, {"start": 2755, "end": 2757, "text": "56", "ref_id": "BIBREF54"}], "ref_spans": [{"start": 849, "end": 856, "text": "Table 1", "ref_id": null}, {"start": 1638, "end": 1758, "text": "Table 1, we summarised clinical and  immunological features of viral respiratory infections by  influenza viruses. 36e44", "ref_id": "TABREF2"}, {"start": 2581, "end": 2590, "text": "(Table 2)", "ref_id": "TABREF1"}], "section": "Influenza viruses"}, {"text": "Coronaviruses are capable of infecting several other organs, as demonstrated by the presence of SARS-CoV in circulating immune cells, neurones, intestinal mucosa, and epithelium of renal distal tubules. 61 Coronavirusesehost interaction can influence susceptibility to CoV infection and progression to severe disease. 3, 11 After entering the body via the respiratory system, a critical step for cell entry and infection is the binding of the envelope S glycoprotein to the epithelial cells through specific receptors. The S protein of the SARS-CoV and SARS-CoV-2 binds to the angiotensinconverting enzyme 2 (ACE2) molecule present on cells through the receptor-binding domain, 62, 63 whilst MERS-CoV binds to the host cell protein dipeptidyl peptidase 4. 64 After binding to the host, the S protein needs to be activated by a cellular protease, the transmembrane protease serine 2, which cleaves S in two subunits liberating the fusion peptide that mediates the fusion of the viral envelope with the cellular membrane. Differences in the structural and dynamic state of the receptor-binding domain 65 and S protein priming 66 between SARS-CoV and SARS-CoV-2 cause higher ACE2-binding affinity of the SARS-CoV-2 and favour its evasion of the immune surveillance, 64 suggesting a potential explanation of the higher SARS-CoV-2 infectivity. 63 Angiotensin-converting enzyme 2 can play a protective role in lung injury, 67 and its downregulation by SARS-CoV can contribute to progression to severe lung injury. 68 On the contrary, MERS-CoV regulates dipeptidyl peptidase 4 receptor in the lungs of smokers and COPD, and this could explain their susceptibility to severe disease. 69 To survive in the host cells, the CoVs adopt multiple strategies to evade detection by the host immune system, allowing active virus replication. The virus can downregulate genes involved in the antigen presentation, such as retinoic-acidinducible gene and melanoma differentiation-associated protein 5, and interfere with intracellular signalling pathways through structural (proteins M and N) and non-structural proteins, so delaying interferon (IFN) expression. 3, 17, 70, 71 Ultimately, a delayed but excessive reaction of the immune system with an uncontrolled expression of cytokines and chemokines (the so-called cytokine storm) associated with virus-induced cytopathic effects will result in lung epithelial and endothelial cell apoptosis and activation of the coagulation cascade, leading to vascular leakage; alveolar oedema; microvascular thrombosis; and, later, cell proliferation with pulmonary fibrosis. 3, 11, 47 Cytokine storm in such patients is associated with more severe lung injury, ICU admission, and worse outcome. 3, 51, 71 To date, no definitive treatment for ", "cite_spans": [{"start": 203, "end": 205, "text": "61", "ref_id": "BIBREF59"}, {"start": 318, "end": 320, "text": "3,", "ref_id": "BIBREF2"}, {"start": 321, "end": 323, "text": "11", "ref_id": "BIBREF10"}, {"start": 678, "end": 681, "text": "62,", "ref_id": "BIBREF60"}, {"start": 682, "end": 684, "text": "63", "ref_id": "BIBREF61"}, {"start": 756, "end": 758, "text": "64", "ref_id": "BIBREF62"}, {"start": 1099, "end": 1101, "text": "65", "ref_id": "BIBREF63"}, {"start": 1263, "end": 1265, "text": "64", "ref_id": "BIBREF62"}, {"start": 1339, "end": 1341, "text": "63", "ref_id": "BIBREF61"}, {"start": 1417, "end": 1419, "text": "67", "ref_id": "BIBREF65"}, {"start": 1508, "end": 1510, "text": "68", "ref_id": "BIBREF66"}, {"start": 1676, "end": 1678, "text": "69", "ref_id": "BIBREF67"}, {"start": 2144, "end": 2146, "text": "3,", "ref_id": "BIBREF2"}, {"start": 2147, "end": 2150, "text": "17,", "ref_id": "BIBREF15"}, {"start": 2151, "end": 2154, "text": "70,", "ref_id": "BIBREF68"}, {"start": 2155, "end": 2157, "text": "71", "ref_id": "BIBREF69"}, {"start": 2597, "end": 2599, "text": "3,", "ref_id": "BIBREF2"}, {"start": 2600, "end": 2603, "text": "11,", "ref_id": "BIBREF10"}, {"start": 2604, "end": 2606, "text": "47", "ref_id": "BIBREF45"}, {"start": 2717, "end": 2719, "text": "3,", "ref_id": "BIBREF2"}, {"start": 2720, "end": 2723, "text": "51,", "ref_id": "BIBREF49"}, {"start": 2724, "end": 2726, "text": "71", "ref_id": "BIBREF69"}], "ref_spans": [], "section": "Clinical signs and symptoms"}, {"text": "Viruses causing severe pulmonary illness can use three epigenetic-regulated ways during hostepathogen interaction: (i) they can affect host DNA methylation signatures and miR-NAs regulating a cassette of genes underlying innate and adaptive antiviral responses; (ii) they can encode for viral proteins that directly interact with the host modified histones; and (iii) they can manipulate the host miRNA processing nuclear machinery to encode viral non-canonical miRNA-like RNA fragments (v-miRNAs) regulating the viral life cycle and immune response. 73 Here, we focus on epigenetic-sensitive mechanisms by which H5N1 and SARS-CoV-2 may affect susceptibility to pulmonary illness by interfering with both innate and adaptive immune responses in humans 74,75 ( Fig. 1 and Table 3 ).", "cite_spans": [{"start": 551, "end": 553, "text": "73", "ref_id": "BIBREF71"}], "ref_spans": [{"start": 760, "end": 766, "text": "Fig. 1", "ref_id": "FIGREF0"}, {"start": 771, "end": 778, "text": "Table 3", "ref_id": "TABREF2"}], "section": "Epigenetic mechanisms and respiratory viral infections"}, {"text": "By combining multi-omics data, H5N1 antagonised the early host antiviral response by altering histone methylation at Type I IFN-sensitive genes. 18 In detail, NS1 viral protein was associated with parallel increased H3K27me3 (repressive mark) and decreased H3K4me3 (active mark) levels favouring a heterochromatin state surrounding the SMAD9L, CFHR1, and DDX58 genes in human airway cells. 18 Viral non-canonical miRNA-like RNA fragments induced cytokine storm and high mortality 76 ; however, v-miRNA biogenesis and function remain to be clarified. 81 Overall, the virus skill to produce functional miRNAs can be also exploited to construct delivery systems of miRNAs based on RNA viruses as molecular vectors. 82", "cite_spans": [{"start": 145, "end": 147, "text": "18", "ref_id": "BIBREF16"}, {"start": 390, "end": 392, "text": "18", "ref_id": "BIBREF16"}, {"start": 480, "end": 482, "text": "76", "ref_id": "BIBREF74"}, {"start": 550, "end": 552, "text": "81", "ref_id": "BIBREF79"}], "ref_spans": [], "section": "Histone modifications"}, {"text": "Severe acute respiratory syndrome coronavirus 2", "cite_spans": [], "ref_spans": [], "section": "Histone modifications"}, {"text": "The high transmissibility and asymptomatic infection rates of SARS-CoV-2 may be caused by a more efficient virus replication and reduced IFN production in lung tissues. 83 As both SARS-CoV-2 and MERS can reprogramme the host epigenome, we hypothesise a possible role for epigenetic drivers underlying susceptibility to COVID-19. Sawalha and colleagues 77 have proposed oxidativestress-induced epigenetic pathways linked to ACE2 deregulation to increase susceptibility and severity of COVID-19 in patients affected by systemic lupus erythematosus (SLE). Indeed, the ACE2 gene CpG hypomethylation status characterising SLE patients could be exacerbated upon SARS-CoV-2 infection leading to further ACE2 protein overexpression in T cells, thus promoting viral infections and dissemination. 77 Disease-related epigenetic perturbations might be hotspots favouring viral infection and provide risk biomarkers useful to stratify sensitiveness to infection and disease severity in patients more prone to disseminate SARS-CoV-2 infection. Consistent with this, a bioinformatic analysis focusing on ACE2 gene has supported the hypothesis for which DNA methylation signatures are dependent on host cell type and gender and age, which are risk factors associated with increased susceptibility to COVID-19 and poor prognosis. 84 ", "cite_spans": [{"start": 169, "end": 171, "text": "83", "ref_id": "BIBREF80"}, {"start": 352, "end": 354, "text": "77", "ref_id": "BIBREF75"}, {"start": 787, "end": 789, "text": "77", "ref_id": "BIBREF75"}, {"start": 1313, "end": 1315, "text": "84", "ref_id": "BIBREF81"}], "ref_spans": [], "section": "DNA methylation"}, {"text": "Patients affected by COVID-19 are at higher risk of thromboembolic events and disseminated intravascular coagulation. 85 As evidence of neutrophil lung infiltration, Barnes and colleagues 78 have emphasised the key role of NETosis in contributing to organ damage and mortality of patients affected by COVID-19. Physiologically, NETosis is a form of innate immunity, in which the neutrophil cell death is guided from histone H3 modifications and release of neutrophil extracellular traps (NETs), complexes of DNA fibres, histones, and proteins aimed to provide a scaffold for platelet adhesion and aggregation to entrap pathogens and avoid their diffusion. 86 Moreover, NETs can induce macrophages to secrete IL1B to further sustain the signalling loop between macrophages and neutrophils, leading to progressive inflammatory damage. Previously, NETosis dysregulation was linked to thrombotic events, 86 ARDS, pulmonary inflammation, and extensive lung damage. 87 Interestingly, there is evidence for which heparin can dismantle NETs and prevent histone-induced platelet aggregation. This might represent the molecular basis for which heparin treatment reduces mortality in subjects affected by severe COVID-19, which develop sepsis-induced coagulopathy. 88 Thus, deoxyribonuclease I-mediated degradation of NETs could provide a therapeutic avenue to suppress excess injury in patients severely affected by COVID-19. 89 ", "cite_spans": [{"start": 118, "end": 120, "text": "85", "ref_id": "BIBREF82"}, {"start": 188, "end": 190, "text": "78", "ref_id": "BIBREF76"}, {"start": 656, "end": 658, "text": "86", "ref_id": "BIBREF83"}, {"start": 900, "end": 902, "text": "86", "ref_id": "BIBREF83"}, {"start": 960, "end": 962, "text": "87", "ref_id": "BIBREF84"}, {"start": 1254, "end": 1256, "text": "88", "ref_id": "BIBREF85"}], "ref_spans": [], "section": "NETosis"}, {"text": "The epitranscriptome of SARS-CoV-2 was analaysed as a possible strategy to dissect the hidden layer of viral regulation. By using nanopore direct RNA sequencing, almost 41 RNA modification sites, mostly located in the AAGAA motif on viral transcripts with shorter poly(A) tails, have been suggested. 90 As poly(A) tails play a relevant role in RNA turnover and stability, the proposed modifications may represent one of the molecular mechanisms by which SARS-CoV-2 evades the host immune response and indices the cytokine storm. 90 Besides, the authors did not identify what type of RNA modifications occur at these sites and the mechanisms underlying COVID-19 pathogenesis. 90", "cite_spans": [{"start": 300, "end": 302, "text": "90", "ref_id": "BIBREF87"}, {"start": 529, "end": 531, "text": "90", "ref_id": "BIBREF87"}], "ref_spans": [], "section": "Epitranscriptome"}, {"text": "Nowadays, the emergence of drug-resistant pathogens continuously increases, thus the discovery of novel drugs or the repositioning of already-approved drugs is needed. 16 Epitherapy may provide further therapeutic opportunities to control viralehost interaction during critical illness. 91 In particular, the current emergence of COVID-19 is guiding researchers towards the possible repurposing of Food and Drug Administration (FDA)-approved epidrugs, 92 including metformin and statins, which may be effective against the novel SARS-CoV-2 infection. Here, we give an update on clinical evidence about the usefulness of novel and FDA-approved drugs interfering with epigenetic pathways, which were applied to ICU patients affected by highly pathogenic strains of influenza virus and CoV, with a particular interest about the novel SARS-CoV-2 (Table 4 ).", "cite_spans": [{"start": 168, "end": 170, "text": "16", "ref_id": "BIBREF14"}, {"start": 287, "end": 289, "text": "91", "ref_id": "BIBREF88"}], "ref_spans": [{"start": 842, "end": 850, "text": "(Table 4", "ref_id": "TABREF3"}], "section": "Epitherapy and immune modulators"}, {"text": "In recent years, a few epidrugs have been introduced into clinic use (e.g. vorinostat and belinostat mainly to treat haematological malignancies), and a wide range of epigeneticbased drugs are undergoing trials, which will clarify whether pharmacological epigenetic modulation is of clinical interest ( Table 5 ). The road from discovery to clinical approval requires long timelines; thus, the repurposing of old drugs interfering with epigenetic pathways is another goal. In this case, epigenetic effect is inevitably going to be 'off-target' in comparison with the drug action used in the first place. Experimental evidence demonstrated that the effects of epidrugs were achieved at lower doses with prolonged exposure, whereas higher drug concentrations were detrimental. However, when ongoing trials will be completed, we will establish clinically if the dose used for epigenetic modification reversal would be the same as, less than, or more than that used for the original purpose.", "cite_spans": [], "ref_spans": [{"start": 303, "end": 310, "text": "Table 5", "ref_id": "TABREF4"}], "section": "Epitherapy and immune modulators"}, {"text": "Curcumin Curcumin, belonging to the histone deacetylase inhibitor (HDACi) group, is a natural polyphenol extracted from turmeric with a wide range of molecular targets and drug activities, including anti-inflammatory properties. Interestingly, after H1N1 infection, curcumin treatment downregulated the secretion of proinflammatory cytokines and expression of the nuclear factor kappa-light-chain enhancer of activated B cell (NF-kB) gene in human macrophages without affecting cell viability. 93 This evidence suggests that curcumin may confer protection against influenza A virus-induced ALI by counteracting the cytokine signalling without damaging the immune system. 93 Interestingly, curcumin and demetoxycurcumin have been indicated as possible inhibitors of COVID-19 virus main protease, which plays a crucial function in controlling viral replication and transcription of SARS-CoV-2, suggesting a putative useful drugetarget interaction to be validated in clinical trials. 100 Apabetalone An international consortium of scientists has identified 50 proteins as putative drug targets against COVID-19. Amongst these targets, bromodomain (BRD) 2/4 would be relevant during interaction with the (E) envelope proteins of SARS-CoV-2 and viral reproduction. 94 By mimicking the histone structure, the (E) envelope proteins might potentially disrupt BRDhistone complexes. BRD proteins are epigenetic players that bind acetylated groups on histone proteins to aid in the recruitment of transcriptional machinery at promoter genes. Apabetalone can directly inhibit BET2/4 proteineSARS-CoV-2 interaction and may downregulate the expression of ACE2 receptors, which are exploited by the surface S glycoprotein to enter into human cells. 101 Currently, apabetalone is not approved by FDA, but has already shown clinical safety as demonstrated during the Phase 3 trial (BETonMACE) focusing on secondary prevention of cardiovascular dysfunction in diabetics. 102 Overall, this evidence suggests that apabetalone may potentially reduce viral infection and replication. In this way, Resverlogix Corporation (https://bit.ly/2CBaEKB) invites collaborators for further research on apabetalone as a putative therapeutic strategy for COVID-19.", "cite_spans": [{"start": 494, "end": 496, "text": "93", "ref_id": "BIBREF90"}, {"start": 671, "end": 673, "text": "93", "ref_id": "BIBREF90"}, {"start": 981, "end": 984, "text": "100", "ref_id": "BIBREF97"}, {"start": 1260, "end": 1262, "text": "94", "ref_id": "BIBREF91"}, {"start": 1734, "end": 1737, "text": "101", "ref_id": "BIBREF98"}, {"start": 1953, "end": 1956, "text": "102", "ref_id": "BIBREF99"}], "ref_spans": [], "section": "De novo epidrugs"}, {"text": "Statins are hydroxymethylglutaryl-coenzyme A reductase inhibitors normalising lipid levels with pleiotropic epigeneticoriented effects by acting as HDACi. As statins also show anti-inflammatory effects, 103 they were thought to block the cytokine storm triggered by influenza viruses. 95 ", "cite_spans": [{"start": 285, "end": 287, "text": "95", "ref_id": "BIBREF92"}], "ref_spans": [], "section": "Influenza viruses"}, {"text": "Clinical evidence about the use of statins in the treatment of viral pneumonia is limited and provided mixed results. Indeed, two trials reported that the anti-inflammatory effects of statins may reduce cardiovascular risk and mortality in ICU patients affected by pneumonia. 109, 110 Otherwise, the results of one randomised clinical trial did not support statin use in those patients with ventilator-associated pneumonia. 111 Currently, there is no clinical or experimental evidence supporting the assertion that statins can improve clinical management of COVID-19. As the rates of acute events and mortality associated with COVID-19 infection are extremely high in patients with cardiovascular diseases (10.8%) and diabetics (7.3%), which generally use statins as primary or secondary prevention, these patients should continue the treatment when SARS-CoV-2 infection is suspected or diagnosed (https://www.acc.org/latest-in-cardiology/features/ /media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/ 02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf). Statins are cleared by the liver metabolism and can increase the level of transaminases in cardio-hepatic patients 112 ; thus, strict evaluation and monitoring of statin therapy should be provided for COVID-19 patients, which commonly show an elevation of the aminotransferases (aspartate transaminase and alanine aminotransferase), with occasional alkaline phosphatase and total bilirubin elevations underlying a high risk for hepatotoxicity. 113, 114 Whether a de novo use of statin therapy may play a key role in preventing COVID-19 complications remains to be elucidated. Remarkably, experimental studies supported the hypothesis for which an early and high dose of statins might be a useful strategy for the treatment of MERS-CoV infections by directly affecting the TLReMYD88eNF-kB axis, which plays a pivotal role during CoV infections. 96, 115, 116 Statins are the most common FDA-approved drugs classified as TLReMYD88 antagonists; moreover, under normal conditions, statins did not strongly alter MYD88 levels, whereas they maintain basal MYD88 levels during stress and hypoxia. 96 This supports that statins might be protective for patients affected by COVID-19. Thus, the putative regulation of MYD88 pathway via statins may be an attractive field of research to explore how to protect innate immune response against novel viral respiratory infections, including SARS-CoV-2.", "cite_spans": [{"start": 276, "end": 280, "text": "109,", "ref_id": "BIBREF106"}, {"start": 281, "end": 284, "text": "110", "ref_id": "BIBREF107"}, {"start": 424, "end": 427, "text": "111", "ref_id": "BIBREF108"}, {"start": 1169, "end": 1172, "text": "112", "ref_id": "BIBREF109"}, {"start": 1498, "end": 1502, "text": "113,", "ref_id": "BIBREF110"}, {"start": 1503, "end": 1506, "text": "114", "ref_id": "BIBREF111"}, {"start": 1898, "end": 1901, "text": "96,", "ref_id": "BIBREF93"}, {"start": 1902, "end": 1906, "text": "115,", "ref_id": "BIBREF112"}, {"start": 1907, "end": 1910, "text": "116", "ref_id": "BIBREF113"}, {"start": 2143, "end": 2145, "text": "96", "ref_id": "BIBREF93"}], "ref_spans": [], "section": "Coronaviruses"}, {"text": "Metformin, belonging to HDACi class, is the first-line antihyperglycaemic drug for type 2 diabetes (T2D) patients, which can indirectly reduce chronic inflammation by normalising glucose levels or directly impact on inflammatory pathways. Recently, Saenwongsa and colleagues 117 have demonstrated that after the trivalent inactivated influenza vaccine (TIV), both the IgG antibody response and IFN-a expression were impaired in T2D patients treated with metformin via repression of rapamycin (mTOR)-mediated pathway and impaired IgG avidity index, leading to increased sensitiveness to H1N1 and H3N2 infection. This suggests that the TIV may not be suitable for T2D patients treated with metformin by emphasising the necessity of developing a more customised strategy for influenza prevention in high-risk groups. Metformin may recover the influenza vaccine responses in T2D patients (treated and non-treated with metformin) by improving the Bcell function via parallel downregulation of inflammation and upregulation of AMPK phosphorylation (active form), a metabolic enzyme involved also in antibody responses. 97 Understanding of the metformin effects on the immune system may guide the repurposing of this drug focused on therapeutic intervention on metabolism in inflammatory diseases.", "cite_spans": [{"start": 275, "end": 278, "text": "117", "ref_id": "BIBREF114"}, {"start": 1113, "end": 1115, "text": "97", "ref_id": "BIBREF94"}], "ref_spans": [], "section": "Influenza viruses"}, {"text": "Immunomodulators and antivirals: could they impact on epigenetic pathways underlying cardiovascular dysfunction in COVID-19?", "cite_spans": [], "ref_spans": [], "section": "Influenza viruses"}, {"text": "The repurposing of both immunomodulators and antivirals, including tocilizumab (TCZ), remdesevir, favipiravir, hydroxychloroquine, and chloroquine, could be a fast way to get effective treatments whilst a preventive vaccine will be available (https://www.who.int/emergencies/diseases/novelcoronavirus-2019). In the current COVID-19 pandemic, TCZ is one of the most promising repurposed drugs under clinical investigation for the treatment of severe hospitalised pneumonia patients. Tocilizumab is a humanised monoclonal antibody that can counteract the cytokine storm by blocking the interleukin-6 (IL-6) receptor signalling associated with a high risk of cardiovascular mortality. 118 Immunomodulators can counteract the overactive inflammatory response, which seems to be the driver of increased disease severity. Many old anti-inflammatory drugs are in clinical trials, such as sarilumab (NCT04315298; Phases 2 and 3) and TCZ (NCT04320615; Phase 3). Besides, the efficacy of antivirals inhibiting viral replication, such as favipiravir (NCT04358549; Phase 2) and remdesevir (NCT04292730; Phase 3), is being evaluated in clinical trials compared with standard of care. The impact of COVID-19 on cardiovascular health is an urgent question for physicians. 119 As epigenetics plays an increasing role in cardiovascular diseases and inflammation, 102, 120 and also during SARS-CoV-2 infection, 77 we emphasised the need to clarify if these drugs could potentially impact the associated cardiac dysfunction modulating the severity of the disease.", "cite_spans": [{"start": 682, "end": 685, "text": "118", "ref_id": "BIBREF115"}, {"start": 1257, "end": 1260, "text": "119", "ref_id": "BIBREF116"}, {"start": 1346, "end": 1350, "text": "102,", "ref_id": "BIBREF99"}, {"start": 1351, "end": 1354, "text": "120", "ref_id": "BIBREF117"}, {"start": 1393, "end": 1395, "text": "77", "ref_id": "BIBREF75"}], "ref_spans": [], "section": "Influenza viruses"}, {"text": "Clinical evidence from rheumatoid arthritis patients demonstrated that TCZ therapy can prevent cardiovascular dysfunction via two main epigenetic-sensitive mechanisms: (i) reduction of NETosis; and (ii) upregulation of miRNA-23, miRNA-146, and miRNA-223 serum levels. 98 Overall, this suggests that TCZ can improve the pro-atherosclerotic status by regulating dyslipidaemias, endothelial dysfunction, inflammation, and oxidative stress. 98 Moreover, TCZ-treated rheumatoid arthritis patients demonstrated a differential expression of 85 lncRNAs in CD14 \u00fe monocytes regulated by IL-6 or tumour necrosis factor-alpha. 99 Preliminary trials have suggested the usefulness of chloroquine or hydroxychloroquine repurposing in the treatment of COVID-19, which is correlated with the ability of these antimalarial agents in interfering with the cellular-mediated viral endocytosis. 121 However, a randomised trial demonstrated that hydroxychloroquine failed in preventing symptomatic infection when taken within 4 days after exposure. 122 At epigenetic level, hydroxychloroquine can exert an inhibitory activity against the polycomb repressive complex 2 (PRC2), responsible of switching chromatin towards a compacted state (inactive gene expression) in blood malignancies. 123 Interestingly, influenza A viruses, MERS-CoV, and SARS-CoV are able to activate the PRC2, which, in turn, increases the levels of H3K27me3 (repressive mark) at the promoters of targeted IFN-stimulated genes to counteract the host antiviral immune response. 124 This let us suggest that also SARS-CoV-2 might use the same mechanisms to inactive IFN-related pathways in infected cells; besides, since polycomb inhibitors have shown a general antiviral activity, 125 it might be useful to investigate whether hydroxychloroquine can directly impact on PRC2 activity in COVID-19. As reported, the clinical effect of i.v. remdesivir seems to be relatively modest; however, a randomised Phase 3 clinical trial (NCT04292899) did not find a significant difference in efficacy between 5-and 10-day courses of this drug. 126 Until now, there is no direct evidence that antivirals, such as remdesevir and favipiravir, would impact epigenetic-sensitive ways during their mechanism of action.", "cite_spans": [{"start": 268, "end": 270, "text": "98", "ref_id": "BIBREF95"}, {"start": 437, "end": 439, "text": "98", "ref_id": "BIBREF95"}, {"start": 616, "end": 618, "text": "99", "ref_id": "BIBREF96"}, {"start": 874, "end": 877, "text": "121", "ref_id": "BIBREF118"}, {"start": 1027, "end": 1030, "text": "122", "ref_id": "BIBREF119"}, {"start": 1265, "end": 1268, "text": "123", "ref_id": "BIBREF120"}, {"start": 1526, "end": 1529, "text": "124", "ref_id": "BIBREF121"}, {"start": 1729, "end": 1732, "text": "125", "ref_id": "BIBREF122"}, {"start": 2079, "end": 2082, "text": "126", "ref_id": "BIBREF123"}], "ref_spans": [], "section": "Influenza viruses"}, {"text": "Targeted epigenetic-sensitive molecular networks are temporally manipulated during virusehost interactions, providing further risk factors for viral shedding and inadequate immune response also in patients affected by COVID-19, in which ACE2 promoter hypomethylation may be one of the relevant drivers. During the current COVID-19 pandemic, we need to understand why a part of the population becomes critically infected when exposed to low viral load, whilst other subjects are less responsive when exposed to high viral loads. As the influenza virus may also promote acute coronary syndromes (which can be reduced by vaccine), 127 the issue of coinfection (i.e. SARS-CoV-2 and influenza viruses) needs to be further explored both in terms of epigenetic-sensitive tandem events and in critical care. For better risk stratification, it would be needed to clarify the SARS-CoV-2 basic mechanisms of action and how these impact on the individual genetic/ epigenetic background and pre-existent cardio-metabolic diseases highly correlated with mortality rate, especially in the elderly. 128, 129 Clinical treatment of mild forms of COVID-19 should not be phobic from fever, which can promote an effective immune response and virus clearance from the body. 130 Ongoing controlled clinical trials would clarify the repositioning of TCZ, whereas curcumin, apabetalone, metformin, and statins could be an effective treatment to protect innate immune response against severe viral respiratory infections. In the era of network medicine, predictive analysis tools are playing a relevant role in addressing the COVID-19 pandemic by providing maps of human proteins interacting with SARS-CoV-2 proteins 101 and a list of candidate repurpose drugs and potential drug combinations targeting SARS-CoV-2. 131 The epigenetic susceptibility to pulmonary viral infections requires further investigation by using the network-oriented analysis to clarify the molecular routes underlying perturbation of the human interactome, 132 in particular in COVID-19 and its impact on cardiovascular health.", "cite_spans": [{"start": 1083, "end": 1087, "text": "128,", "ref_id": "BIBREF125"}, {"start": 1088, "end": 1091, "text": "129", "ref_id": "BIBREF126"}, {"start": 1252, "end": 1255, "text": "130", "ref_id": "BIBREF127"}, {"start": 1789, "end": 1792, "text": "131", "ref_id": "BIBREF128"}, {"start": 2005, "end": 2008, "text": "132", "ref_id": "BIBREF129"}], "ref_spans": [], "section": "Concluding remarks"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Epidemiology of 2009 pandemic influenza A (H1N1) in the United States", "authors": [{"first": "M", "middle": ["A"], "last": "Jhung", "suffix": ""}, {"first": "D", "middle": [], "last": "Swerdlow", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Olsen", "suffix": ""}], "year": 2011, "venue": "Clin Infect Dis", "volume": "52", "issn": "", "pages": "13--26", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Epidemiology of human infections with avian influenza A(H7N9) virus in China", "authors": [{"first": "L", "middle": [], "last": "Qun", "suffix": ""}, {"first": "Z", "middle": [], "last": "Lei", "suffix": ""}, {"first": "Z", "middle": [], "last": "Minghao", "suffix": ""}, {"first": "C", "middle": [], "last": "Zhiping", "suffix": ""}, {"first": "L", "middle": [], "last": "Furong", "suffix": ""}, {"first": "W", "middle": [], "last": "Huanyu", "suffix": ""}], "year": 2014, "venue": "N Engl J Med", "volume": "370", "issn": "", "pages": "520--552", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "SARS and MERS: recent insights into emerging coronaviruses", "authors": [{"first": "E", "middle": [], "last": "De Wit", "suffix": ""}, {"first": "N", "middle": [], "last": "Van Doremalen", "suffix": ""}, {"first": "D", "middle": [], "last": "Falzarano", "suffix": ""}, {"first": "V", "middle": ["J"], "last": "Munster", "suffix": ""}], "year": 2016, "venue": "Nat Rev Microbiol", "volume": "14", "issn": "", "pages": "523--557", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Another decade, another coronavirus", "authors": [{"first": "S", "middle": [], "last": "Perlman", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "382", "issn": "", "pages": "760--762", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "A novel coronavirus from patients with pneumonia in China", "authors": [{"first": "N", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "D", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}], "year": 2019, "venue": "N Engl J Med", "volume": "382", "issn": "", "pages": "727--760", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Lung pathology of fatal severe acute respiratory syndrome", "authors": [{"first": "J", "middle": ["M"], "last": "Nicholls", "suffix": ""}, {"first": "L", "middle": ["L"], "last": "Poon", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Lee", "suffix": ""}], "year": 2003, "venue": "Lancet", "volume": "361", "issn": "", "pages": "1773--1781", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella", "authors": [{"first": "B", "middle": ["T"], "last": "Bradley", "suffix": ""}, {"first": "A", "middle": [], "last": "Bryan", "suffix": ""}], "year": 2019, "venue": "Semin Diagn Pathol", "volume": "36", "issn": "", "pages": "152--161", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways", "authors": [{"first": "Y", "middle": [], "last": "Ding", "suffix": ""}, {"first": "L", "middle": [], "last": "He", "suffix": ""}, {"first": "Q", "middle": [], "last": "Zhang", "suffix": ""}], "year": 2004, "venue": "J Pathol", "volume": "203", "issn": "", "pages": "622--652", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Into the eye of the cytokine storm", "authors": [{"first": "J", "middle": ["R"], "last": "Tisoncik", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Korth", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Simmons", "suffix": ""}, {"first": "J", "middle": [], "last": "Farrar", "suffix": ""}, {"first": "T", "middle": ["R"], "last": "Martin", "suffix": ""}, {"first": "M", "middle": ["G"], "last": "Katze", "suffix": ""}], "year": 2012, "venue": "Microbiol Mol Biol Rev", "volume": "76", "issn": "", "pages": "16--32", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "The inflammatory response triggered by Influenza virus: a two edged sword", "authors": [{"first": "L", "middle": ["P"], "last": "Tavares", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Teixeira", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Garcia", "suffix": ""}], "year": 2017, "venue": "Inflamm Res", "volume": "66", "issn": "", "pages": "283--302", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Coronavirus infections and immune responses", "authors": [{"first": "G", "middle": [], "last": "Li", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lai", "suffix": ""}], "year": 2020, "venue": "J Med Virol", "volume": "92", "issn": "", "pages": "424--456", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Sch\u20ac afer A, Baric RS. Epigenetic landscape during coronavirus infection", "authors": [{"first": "S", "middle": [], "last": "Zaim", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Chong", "suffix": ""}, {"first": "V", "middle": [], "last": "Sankaranarayanan", "suffix": ""}, {"first": "A", "middle": [], "last": "Harky", "suffix": ""}], "year": 2017, "venue": "Curr Probl Cardiol", "volume": "45", "issn": "8", "pages": "100618--100631", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Epigenetic control of immunity", "authors": [{"first": "M", "middle": [], "last": "Busslinger", "suffix": ""}, {"first": "A", "middle": [], "last": "Tarakhovsky", "suffix": ""}], "year": 2014, "venue": "Cold Spring Harb Perspect Biol", "volume": "6", "issn": "", "pages": "", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Epigenetics mechanisms in multiorgan dysfunction syndrome", "authors": [{"first": "E", "middle": [], "last": "Crimi", "suffix": ""}, {"first": "S", "middle": [], "last": "Cirri", "suffix": ""}, {"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "C", "middle": [], "last": "Napoli", "suffix": ""}], "year": 2019, "venue": "Anesth Analg", "volume": "129", "issn": "", "pages": "1422--1454", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Clinical epigenetics and multidrug-resistant bacterial infections: host remodelling in critical illness", "authors": [{"first": "E", "middle": [], "last": "Crimi", "suffix": ""}, {"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "S", "middle": [], "last": "Cirri", "suffix": ""}, {"first": "R", "middle": [], "last": "Mutesi", "suffix": ""}, {"first": "M", "middle": [], "last": "Faenza", "suffix": ""}, {"first": "C", "middle": [], "last": "Napoli", "suffix": ""}], "year": 2020, "venue": "Epigenetics", "volume": "", "issn": "", "pages": "1--13", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Antagonism of dsRNA-induced innate immune pathways by NS4a and NS4b accessory proteins during MERS coronavirus infection", "authors": [{"first": "C", "middle": ["E"], "last": "Comar", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Goldstein", "suffix": ""}, {"first": "Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "B", "middle": [], "last": "Yount", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Baric", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Weiss", "suffix": ""}], "year": 2019, "venue": "mBio", "volume": "10", "issn": "", "pages": "319--338", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses", "authors": [{"first": "V", "middle": ["D"], "last": "Menachery", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Eisfeld", "suffix": ""}, {"first": "A", "middle": [], "last": "Sch\u20ac Afer", "suffix": ""}], "year": 2014, "venue": "mBio", "volume": "5", "issn": "", "pages": "1174--1188", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Suppression of the antiviral response by an influenza histone mimic", "authors": [{"first": "I", "middle": [], "last": "Marazzi", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Ho", "suffix": ""}, {"first": "J", "middle": [], "last": "Kim", "suffix": ""}], "year": 2012, "venue": "Nature", "volume": "483", "issn": "", "pages": "428--461", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Structural basis for histone mimicry and hijacking of host proteins by influenza virus protein NS1", "authors": [{"first": "S", "middle": [], "last": "Qin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "W", "middle": [], "last": "Tempel", "suffix": ""}], "year": 2014, "venue": "Nat Commun", "volume": "5", "issn": "", "pages": "", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "The miRNA complexes against coronaviruses COVID-19", "authors": [{"first": "A", "middle": [], "last": "Ivashchenko", "suffix": ""}, {"first": "A", "middle": [], "last": "Rakhmetullina", "suffix": ""}, {"first": "A", "middle": [], "last": "Akimniyazova", "suffix": ""}, {"first": "D", "middle": [], "last": "Aisina", "suffix": ""}, {"first": "A", "middle": [], "last": "Pyrkova", "suffix": ""}, {"first": "Mers-Cov", "middle": [], "last": "Sars-Cov", "suffix": ""}], "year": 2020, "venue": "Res Sq", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.21203/rs.3.rs-19592/v1"]}}, "BIBREF20": {"ref_id": "b20", "title": "Implications of the virusencoded miRNA and host miRNA in the pathogenicity of SARS-CoV-2. arXiv 2020. Advance Access published on", "authors": [{"first": "L", "middle": [], "last": "Zhi", "suffix": ""}, {"first": "W", "middle": [], "last": "Jianwei", "suffix": ""}, {"first": "X", "middle": [], "last": "Yuyu", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Epigenetic coordination of acute systemic inflammation: potential therapeutic targets", "authors": [{"first": "V", "middle": [], "last": "Vachharajani", "suffix": ""}, {"first": "T", "middle": [], "last": "Liu", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Mccall", "suffix": ""}], "year": 2014, "venue": "Expert Rev Clin Immunol", "volume": "10", "issn": "", "pages": "1141--50", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Epigeneticsensitive pathways in personalized therapy of major cardiovascular diseases", "authors": [{"first": "C", "middle": [], "last": "Schiano", "suffix": ""}, {"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "M", "middle": [], "last": "Franzese", "suffix": ""}], "year": 2020, "venue": "Pharmacol Ther", "volume": "210", "issn": "", "pages": "", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Zoonotic infections with avian influenza A viruses and vaccine preparedness: a game of mix and match", "authors": [{"first": "P", "middle": ["N"], "last": "Pascua", "suffix": ""}, {"first": "Y", "middle": ["K"], "last": "Choi", "suffix": ""}], "year": 2014, "venue": "Clin Exp Vaccine Res", "volume": "3", "issn": "", "pages": "140--148", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus", "authors": [{"first": "E", "middle": ["C"], "last": "Claas", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Osterhaus", "suffix": ""}, {"first": "R", "middle": [], "last": "Van Beek", "suffix": ""}], "year": 1998, "venue": "Lancet", "volume": "351", "issn": "", "pages": "472--479", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Avian influenza A (H5N1) infection in humans", "authors": [{"first": "J", "middle": ["H"], "last": "Beigel", "suffix": ""}, {"first": "J", "middle": [], "last": "Farrar", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Han", "suffix": ""}], "year": 2005, "venue": "N Engl J Med", "volume": "353", "issn": "", "pages": "1374--85", "other_ids": {}}, "BIBREF26": {"ref_id": "b26", "title": "Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus", "authors": [{"first": "A", "middle": ["N"], "last": "Abdel-Ghafar", "suffix": ""}, {"first": "T", "middle": [], "last": "Chotpitayasunondh", "suffix": ""}], "year": 2008, "venue": "N Engl J Med", "volume": "358", "issn": "", "pages": "261--73", "other_ids": {}}, "BIBREF27": {"ref_id": "b27", "title": "Critically ill patients with 2009 influenza A(H1N1) in Mexico", "authors": [{"first": "G", "middle": [], "last": "Dom\u00ednguez-Cherit", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Lapinsky", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Macias", "suffix": ""}], "year": 2009, "venue": "JAMA", "volume": "302", "issn": "", "pages": "1880--1887", "other_ids": {}}, "BIBREF28": {"ref_id": "b28", "title": "Emergence of a novel swine-origin influenza A (H1N1) virus in humans", "authors": [{"first": "F", "middle": ["S"], "last": "Dawood", "suffix": ""}, {"first": "S", "middle": [], "last": "Jain", "suffix": ""}, {"first": "L", "middle": [], "last": "Finelli", "suffix": ""}], "year": 2009, "venue": "Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team", "volume": "360", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1056/NEJMoa0903810"]}}, "BIBREF29": {"ref_id": "b29", "title": "Hospitalized patients with 2009 H1N1 influenza in the United States", "authors": [{"first": "S", "middle": [], "last": "Jain", "suffix": ""}, {"first": "L", "middle": [], "last": "Kamimoto", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Bramley", "suffix": ""}], "year": 2009, "venue": "N Engl J Med", "volume": "361", "issn": "", "pages": "", "other_ids": {}}, "BIBREF30": {"ref_id": "b30", "title": "Critically ill patients with 2009 influenza A(H1N1) infection in Canada", "authors": [{"first": "A", "middle": [], "last": "Kumar", "suffix": ""}, {"first": "R", "middle": [], "last": "Zarychanski", "suffix": ""}, {"first": "R", "middle": [], "last": "Pinto", "suffix": ""}], "year": 2009, "venue": "JAMA", "volume": "302", "issn": "", "pages": "1872--1881", "other_ids": {}}, "BIBREF31": {"ref_id": "b31", "title": "Critical care services and 2009 H1N1 influenza in Australia and New Zealand", "authors": [{"first": "", "middle": [], "last": "Anzic Influenza Investigators", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Webb", "suffix": ""}, {"first": "", "middle": [], "last": "Pettil\u20ac A V", "suffix": ""}, {"first": "I", "middle": [], "last": "Seppelt", "suffix": ""}], "year": 2009, "venue": "N Engl J Med", "volume": "361", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1056/NEJMoa0908481"]}}, "BIBREF32": {"ref_id": "b32", "title": "Influenza A (H1N1pdm09)-related critical illness and mortality in Mexico and Canada", "authors": [{"first": "G", "middle": [], "last": "Dominguez-Cherit", "suffix": ""}, {"first": "De", "middle": [], "last": "La Torre", "suffix": ""}, {"first": "A", "middle": [], "last": "Rishu", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2014, "venue": "Crit Care Med", "volume": "44", "issn": "", "pages": "1861--70", "other_ids": {}}, "BIBREF33": {"ref_id": "b33", "title": "Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus", "authors": [{"first": "A", "middle": ["M"], "last": "Iorio", "suffix": ""}, {"first": "O", "middle": [], "last": "Bistoni", "suffix": ""}, {"first": "M", "middle": [], "last": "Galdiero", "suffix": ""}], "year": 2012, "venue": "Vaccine", "volume": "30", "issn": "", "pages": "1617--1640", "other_ids": {}}, "BIBREF34": {"ref_id": "b34", "title": "Pathology of fatal human infection associated with avian influenza A H5N1 virus", "authors": [{"first": "K", "middle": ["F"], "last": "To", "suffix": ""}, {"first": "P", "middle": ["K"], "last": "Chan", "suffix": ""}, {"first": "K", "middle": ["F"], "last": "Chan", "suffix": ""}], "year": 2001, "venue": "J Med Virol", "volume": "63", "issn": "", "pages": "242--248", "other_ids": {}}, "BIBREF35": {"ref_id": "b35", "title": "Re-emergence of fatal human influenza A subtype H5N1 disease", "authors": [{"first": "J", "middle": ["S"], "last": "Peiris", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Yu", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Leung", "suffix": ""}], "year": 2004, "venue": "Lancet", "volume": "363", "issn": "", "pages": "617--626", "other_ids": {}}, "BIBREF36": {"ref_id": "b36", "title": "Lung pathology in fatal novel human influenza A (H1N1) infection", "authors": [{"first": "T", "middle": [], "last": "Mauad", "suffix": ""}, {"first": "L", "middle": ["A"], "last": "Hajjar", "suffix": ""}, {"first": "G", "middle": ["D"], "last": "Callegari", "suffix": ""}], "year": 2010, "venue": "Am J Respir Crit Care Med", "volume": "181", "issn": "", "pages": "72--81", "other_ids": {}}, "BIBREF37": {"ref_id": "b37", "title": "Pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States", "authors": [{"first": "W", "middle": ["J"], "last": "Shieh", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Blau", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Denison", "suffix": ""}], "year": 2009, "venue": "Am J Pathol", "volume": "177", "issn": "", "pages": "166--75", "other_ids": {}}, "BIBREF38": {"ref_id": "b38", "title": "Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis", "authors": [{"first": "R", "middle": [], "last": "Gao", "suffix": ""}, {"first": "J", "middle": [], "last": "Bhatnagar", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Blau", "suffix": ""}], "year": 2013, "venue": "Am J Pathol", "volume": "183", "issn": "", "pages": "1258--68", "other_ids": {}}, "BIBREF39": {"ref_id": "b39", "title": "Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host", "authors": [{"first": "J", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "S", "middle": [], "last": "Perlman", "suffix": ""}], "year": 2018, "venue": "Curr Opin Virol", "volume": "28", "issn": "", "pages": "43--52", "other_ids": {}}, "BIBREF40": {"ref_id": "b40", "title": "The cytokine storm of severe influenza and development of immunomodulatory therapy", "authors": [{"first": "Q", "middle": [], "last": "Liu", "suffix": ""}, {"first": "Y-H", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "Yang Z-Q", "middle": [], "last": "", "suffix": ""}], "year": 2016, "venue": "Cell Mol Immunol", "volume": "13", "issn": "", "pages": "3--10", "other_ids": {}}, "BIBREF41": {"ref_id": "b41", "title": "Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity", "authors": [{"first": "K", "middle": [], "last": "Schoen", "suffix": ""}, {"first": "N", "middle": [], "last": "Horvat", "suffix": ""}, {"first": "Nfc", "middle": [], "last": "Guerreiro", "suffix": ""}, {"first": "I", "middle": [], "last": "De Castro", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "De Giassi", "suffix": ""}], "year": 2019, "venue": "BMC Infect Dis", "volume": "19", "issn": "", "pages": "", "other_ids": {}}, "BIBREF42": {"ref_id": "b42", "title": "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia", "authors": [{"first": "M", "middle": ["D"], "last": "De Jong", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Simmons", "suffix": ""}, {"first": "T", "middle": ["T"], "last": "Thanh", "suffix": ""}], "year": 2006, "venue": "Nat Med", "volume": "12", "issn": "", "pages": "1203--1210", "other_ids": {}}, "BIBREF43": {"ref_id": "b43", "title": "Origin and evolution of pathogenic coronaviruses", "authors": [{"first": "J", "middle": [], "last": "Cui", "suffix": ""}, {"first": "F", "middle": [], "last": "Li", "suffix": ""}, {"first": "Z", "middle": ["L"], "last": "Shi", "suffix": ""}], "year": 2019, "venue": "Nat Rev Microbiol", "volume": "17", "issn": "", "pages": "181--92", "other_ids": {}}, "BIBREF44": {"ref_id": "b44", "title": "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding", "authors": [{"first": "R", "middle": [], "last": "Lu", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "565--74", "other_ids": {}}, "BIBREF45": {"ref_id": "b45", "title": "Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV", "authors": [{"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "X", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "Q", "middle": [], "last": "Tong", "suffix": ""}], "year": 2020, "venue": "J Med Virol", "volume": "92", "issn": "", "pages": "491--495", "other_ids": {}}, "BIBREF46": {"ref_id": "b46", "title": "The epidemic of 2019-novelcoronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future", "authors": [{"first": "J", "middle": ["Y"], "last": "Li", "suffix": ""}, {"first": "Z", "middle": [], "last": "You", "suffix": ""}, {"first": "Q", "middle": [], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "Microbe. Infect", "volume": "22", "issn": "", "pages": "80--85", "other_ids": {}}, "BIBREF47": {"ref_id": "b47", "title": "SARS and other coronaviruses as causes of pneumonia", "authors": [{"first": "Y", "middle": [], "last": "Yin", "suffix": ""}, {"first": "R", "middle": ["G"], "last": "Wunderink", "suffix": ""}, {"first": "", "middle": [], "last": "Mers", "suffix": ""}], "year": 2018, "venue": "Respirology", "volume": "23", "issn": "", "pages": "130--137", "other_ids": {}}, "BIBREF48": {"ref_id": "b48", "title": "Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission", "authors": [{"first": "D", "middle": ["S"], "last": "Hui", "suffix": ""}, {"first": "E", "middle": ["I"], "last": "Azhar", "suffix": ""}, {"first": "Y", "middle": ["J"], "last": "Kim", "suffix": ""}, {"first": "Z", "middle": ["A"], "last": "Memish", "suffix": ""}, {"first": "M", "middle": ["D"], "last": "Oh", "suffix": ""}, {"first": "A", "middle": [], "last": "Zumla", "suffix": ""}], "year": 2018, "venue": "Lancet Infect Dis", "volume": "18", "issn": "", "pages": "217--244", "other_ids": {}}, "BIBREF49": {"ref_id": "b49", "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", "authors": [{"first": "C", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "497--506", "other_ids": {}}, "BIBREF50": {"ref_id": "b50", "title": "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study", "authors": [{"first": "N", "middle": [], "last": "Chen", "suffix": ""}, {"first": "M", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "X", "middle": [], "last": "Dong", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "507--520", "other_ids": {}}, "BIBREF51": {"ref_id": "b51", "title": "Clinical characteristics of coronavirus disease 2019 in China", "authors": [{"first": "W", "middle": ["J"], "last": "Guan", "suffix": ""}, {"first": "Z", "middle": ["Y"], "last": "Ni", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "382", "issn": "", "pages": "1708--1728", "other_ids": {}}, "BIBREF52": {"ref_id": "b52", "title": "Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area", "authors": [{"first": "S", "middle": [], "last": "Richardson", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Hirsch", "suffix": ""}, {"first": "M", "middle": [], "last": "Narasimhan", "suffix": ""}], "year": 2020, "venue": "JAMA", "volume": "323", "issn": "", "pages": "2052--2061", "other_ids": {}}, "BIBREF53": {"ref_id": "b53", "title": "Cardiovascular disease, drug therapy, and mortality in Covid-19", "authors": [{"first": "M", "middle": ["R"], "last": "Mehra", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Desai", "suffix": ""}, {"first": "S", "middle": [], "last": "Kuy", "suffix": ""}, {"first": "T", "middle": ["D"], "last": "Henry", "suffix": ""}, {"first": "A", "middle": ["N"], "last": "Patel", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "382", "issn": "", "pages": "", "other_ids": {}}, "BIBREF54": {"ref_id": "b54", "title": "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region", "authors": [{"first": "G", "middle": [], "last": "Grasselli", "suffix": ""}, {"first": "A", "middle": [], "last": "Zangrillo", "suffix": ""}, {"first": "A", "middle": [], "last": "Zanella", "suffix": ""}], "year": 2020, "venue": "Italy JAMA", "volume": "323", "issn": "", "pages": "1574--81", "other_ids": {}}, "BIBREF55": {"ref_id": "b55", "title": "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study", "authors": [{"first": "T", "middle": [], "last": "Chen", "suffix": ""}, {"first": "D", "middle": [], "last": "Wu", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}], "year": 2020, "venue": "BMJ", "volume": "368", "issn": "", "pages": "", "other_ids": {}}, "BIBREF56": {"ref_id": "b56", "title": "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study", "authors": [{"first": "H", "middle": [], "last": "Shi", "suffix": ""}, {"first": "X", "middle": [], "last": "Han", "suffix": ""}, {"first": "N", "middle": [], "last": "Jiang", "suffix": ""}], "year": 2020, "venue": "Lancet Infect Dis", "volume": "20", "issn": "", "pages": "425--459", "other_ids": {}}, "BIBREF57": {"ref_id": "b57", "title": "Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies", "authors": [{"first": "S", "middle": [], "last": "Tian", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xiong", "suffix": ""}, {"first": "H", "middle": [], "last": "Liu", "suffix": ""}], "year": 2020, "venue": "Mod Pathol", "volume": "33", "issn": "", "pages": "1007--1021", "other_ids": {}}, "BIBREF58": {"ref_id": "b58", "title": "Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates", "authors": [{"first": "D", "middle": ["L"], "last": "Ng", "suffix": ""}, {"first": "Al", "middle": [], "last": "Hosani", "suffix": ""}, {"first": "F", "middle": [], "last": "Keating", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "", "suffix": ""}], "year": 2014, "venue": "Am J Pathol", "volume": "186", "issn": "", "pages": "652--660", "other_ids": {}}, "BIBREF59": {"ref_id": "b59", "title": "Multiple organ infection and the pathogenesis of SARS", "authors": [{"first": "J", "middle": [], "last": "Gu", "suffix": ""}, {"first": "E", "middle": [], "last": "Gong", "suffix": ""}, {"first": "B", "middle": [], "last": "Zhang", "suffix": ""}], "year": 2005, "venue": "J Exp Med", "volume": "202", "issn": "", "pages": "415--439", "other_ids": {}}, "BIBREF60": {"ref_id": "b60", "title": "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target", "authors": [{"first": "H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Penninger", "suffix": ""}, {"first": "Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhong", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Slutsky", "suffix": ""}], "year": 2020, "venue": "Intensive Care Med", "volume": "46", "issn": "", "pages": "586--90", "other_ids": {}}, "BIBREF61": {"ref_id": "b61", "title": "Cell entry mechanisms of SARS-CoV-2", "authors": [{"first": "J", "middle": [], "last": "Shang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wan", "suffix": ""}, {"first": "C", "middle": [], "last": "Luo", "suffix": ""}], "year": 2020, "venue": "Proc Natl Acad Sci U S A", "volume": "117", "issn": "", "pages": "11727--11761", "other_ids": {}}, "BIBREF62": {"ref_id": "b62", "title": "Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome", "authors": [{"first": "D", "middle": ["K"], "last": "Meyerholz", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Lambertz", "suffix": ""}, {"first": "P", "middle": ["B"], "last": "Mccray", "suffix": ""}], "year": 2016, "venue": "Am J Pathol", "volume": "186", "issn": "", "pages": "78--86", "other_ids": {}}, "BIBREF63": {"ref_id": "b63", "title": "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", "authors": [{"first": "D", "middle": [], "last": "Wrapp", "suffix": ""}, {"first": "N", "middle": [], "last": "Wang", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Corbett", "suffix": ""}], "year": 2020, "venue": "Science", "volume": "367", "issn": "", "pages": "1260--1263", "other_ids": {}}, "BIBREF64": {"ref_id": "b64", "title": "The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade", "authors": [{"first": "B", "middle": [], "last": "Coutard", "suffix": ""}, {"first": "C", "middle": [], "last": "Valle", "suffix": ""}, {"first": "X", "middle": [], "last": "De Lamballerie", "suffix": ""}, {"first": "B", "middle": [], "last": "Canard", "suffix": ""}, {"first": "N", "middle": ["G"], "last": "Seidah", "suffix": ""}, {"first": "E", "middle": [], "last": "Decroly", "suffix": ""}], "year": 2020, "venue": "Antivir Res", "volume": "176", "issn": "", "pages": "", "other_ids": {}}, "BIBREF65": {"ref_id": "b65", "title": "Angiotensin-converting enzyme 2 protects from severe acute lung failure", "authors": [{"first": "Y", "middle": [], "last": "Imai", "suffix": ""}, {"first": "K", "middle": [], "last": "Kuba", "suffix": ""}, {"first": "S", "middle": [], "last": "Rao", "suffix": ""}], "year": 2005, "venue": "Nature", "volume": "436", "issn": "", "pages": "112--118", "other_ids": {}}, "BIBREF66": {"ref_id": "b66", "title": "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirusinduced lung injury", "authors": [{"first": "K", "middle": [], "last": "Kuba", "suffix": ""}, {"first": "Y", "middle": [], "last": "Imai", "suffix": ""}, {"first": "S", "middle": [], "last": "Rao", "suffix": ""}], "year": 2005, "venue": "Nat Med", "volume": "11", "issn": "", "pages": "875--884", "other_ids": {}}, "BIBREF67": {"ref_id": "b67", "title": "DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients", "authors": [{"first": "Ljm", "middle": [], "last": "Seys", "suffix": ""}, {"first": "W", "middle": [], "last": "Widagdo", "suffix": ""}, {"first": "F", "middle": ["M"], "last": "Verhamme", "suffix": ""}], "year": 2018, "venue": "Clin Infect Dis", "volume": "66", "issn": "", "pages": "45--53", "other_ids": {}}, "BIBREF68": {"ref_id": "b68", "title": "Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus", "authors": [{"first": "L", "middle": [], "last": "Josset", "suffix": ""}, {"first": "V", "middle": ["D"], "last": "Menachery", "suffix": ""}, {"first": "L", "middle": ["E"], "last": "Gralinski", "suffix": ""}], "year": 2013, "venue": "mBio", "volume": "4", "issn": "", "pages": "165--178", "other_ids": {}}, "BIBREF69": {"ref_id": "b69", "title": "Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?", "authors": [{"first": "E", "middle": [], "last": "Faure", "suffix": ""}, {"first": "J", "middle": [], "last": "Poissy", "suffix": ""}, {"first": "A", "middle": [], "last": "Goffard", "suffix": ""}], "year": 2014, "venue": "PLoS One", "volume": "9", "issn": "", "pages": "", "other_ids": {}}, "BIBREF70": {"ref_id": "b70", "title": "An update on current therapeutic drugs treating COVID-19", "authors": [{"first": "R", "middle": [], "last": "Wu", "suffix": ""}, {"first": "L", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": ["D"], "last": "Kuo", "suffix": ""}], "year": null, "venue": "Curr Pharmacol Rep", "volume": "2020", "issn": "", "pages": "1--15", "other_ids": {}}, "BIBREF71": {"ref_id": "b71", "title": "Epigenetics of hostepathogen interactions: the road ahead and the road behind", "authors": [{"first": "E", "middle": [], "last": "G Omez-D\u00edaz", "suffix": ""}, {"first": "Jord", "middle": [], "last": "", "suffix": ""}, {"first": "M", "middle": [], "last": "Peinado", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Rivero", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2012, "venue": "PLoS Pathog", "volume": "8", "issn": "", "pages": "", "other_ids": {}}, "BIBREF72": {"ref_id": "b72", "title": "Early local immune defences in the respiratory tract", "authors": [{"first": "A", "middle": [], "last": "Iwasaki", "suffix": ""}, {"first": "E", "middle": [], "last": "Foxman", "suffix": ""}, {"first": "R", "middle": [], "last": "Molony", "suffix": ""}], "year": 2017, "venue": "Nat Rev Immunol", "volume": "17", "issn": "", "pages": "7--20", "other_ids": {}}, "BIBREF73": {"ref_id": "b73", "title": "Antiviral B cell and T cell immunity in the lungs", "authors": [{"first": "C", "middle": [], "last": "Chiu", "suffix": ""}, {"first": "P", "middle": [], "last": "Openshaw", "suffix": ""}], "year": 2015, "venue": "Nat Immunol", "volume": "16", "issn": "", "pages": "18--26", "other_ids": {}}, "BIBREF74": {"ref_id": "b74", "title": "H5N1 influenza virus-specific miRNA-like small RNA increases cytokine production and mouse mortality via targeting poly(rC)-binding protein 2", "authors": [{"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "Z", "middle": [], "last": "Fu", "suffix": ""}, {"first": "H", "middle": [], "last": "Liang", "suffix": ""}], "year": 2018, "venue": "Cell Res", "volume": "28", "issn": "", "pages": "157--71", "other_ids": {}}, "BIBREF75": {"ref_id": "b75", "title": "Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients", "authors": [{"first": "A", "middle": ["H"], "last": "Sawalha", "suffix": ""}, {"first": "M", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "P", "middle": [], "last": "Coit", "suffix": ""}, {"first": "Q", "middle": [], "last": "Lu", "suffix": ""}], "year": 2020, "venue": "Clin Immunol", "volume": "215", "issn": "", "pages": "", "other_ids": {}}, "BIBREF76": {"ref_id": "b76", "title": "Targeting potential drivers of COVID-19: neutrophil extracellular traps", "authors": [{"first": "B", "middle": ["J"], "last": "Barnes", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Adrover", "suffix": ""}, {"first": "A", "middle": [], "last": "Baxter-Stoltzfus", "suffix": ""}], "year": 2020, "venue": "J Exp Med", "volume": "217", "issn": "", "pages": "", "other_ids": {}}, "BIBREF77": {"ref_id": "b77", "title": "Engineered RNA viral synthesis of microRNAs", "authors": [{"first": "A", "middle": [], "last": "Varble", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Chua", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Perez", "suffix": ""}, {"first": "B", "middle": [], "last": "Manicassamy", "suffix": ""}, {"first": "A", "middle": [], "last": "Garc\u00eda-Sastre", "suffix": ""}, {"first": "", "middle": [], "last": "Br", "suffix": ""}], "year": 2010, "venue": "Proc Natl Acad Sci U S A", "volume": "107", "issn": "", "pages": "11519--11543", "other_ids": {}}, "BIBREF78": {"ref_id": "b78", "title": "Influenza A virus expresses high levels of an unusual class of small viral leader RNAs in infected cells", "authors": [{"first": "J", "middle": ["L"], "last": "Umbach", "suffix": ""}, {"first": "H", "middle": ["L"], "last": "Yen", "suffix": ""}, {"first": "L", "middle": ["L"], "last": "Poon", "suffix": ""}, {"first": "B", "middle": ["R"], "last": "Cullen", "suffix": ""}], "year": 2010, "venue": "mBio", "volume": "1", "issn": "", "pages": "204--214", "other_ids": {}}, "BIBREF79": {"ref_id": "b79", "title": "tenOever BR. RNA viruses and the host microRNA machinery", "authors": [{"first": "L", "middle": ["C"], "last": "Aguado", "suffix": ""}], "year": 2013, "venue": "Nat Rev Microbiol", "volume": "14", "issn": "", "pages": "169--80", "other_ids": {}}, "BIBREF80": {"ref_id": "b80", "title": "Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19", "authors": [{"first": "H", "middle": [], "last": "Chu", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Chan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "Clin Infect Dis", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1093/cid/ciaa410"]}}, "BIBREF81": {"ref_id": "b81", "title": "DNA methylation analysis of the COVID-19 host cell receptor, angiotensin I converting enzyme 2 gene (ACE2) in the respiratory system reveal age and gender differences", "authors": [{"first": "M", "middle": ["J"], "last": "Corley", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Ndhlovu", "suffix": ""}], "year": null, "venue": "", "volume": "2020", "issn": "", "pages": "", "other_ids": {"DOI": ["10.20944/preprints202003.0295.v1"]}}, "BIBREF82": {"ref_id": "b82", "title": "Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified?", "authors": [{"first": "M", "middle": [], "last": "Cattaneo", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Bertinato", "suffix": ""}, {"first": "S", "middle": [], "last": "Birocchi", "suffix": ""}], "year": 2020, "venue": "Thromb Haemost", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1055/s-0040-1712097"]}}, "BIBREF83": {"ref_id": "b83", "title": "Interplay between genetics and epigenetics in modulating the risk of venous thromboembolism: a new challenge for personalized therapy", "authors": [{"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "D", "middle": [], "last": "Costa", "suffix": ""}, {"first": "T", "middle": [], "last": "Infante", "suffix": ""}, {"first": "R", "middle": [], "last": "Lucchese", "suffix": ""}, {"first": "F", "middle": [], "last": "Donatelli", "suffix": ""}, {"first": "C", "middle": [], "last": "Napoli", "suffix": ""}], "year": 2019, "venue": "Thromb Res", "volume": "177", "issn": "", "pages": "145--53", "other_ids": {}}, "BIBREF84": {"ref_id": "b84", "title": "Neutrophil extracellular traps are elevated in patients with pneumonia-related acute respiratory distress syndrome", "authors": [{"first": "I", "middle": [], "last": "Bendib", "suffix": ""}, {"first": "L", "middle": [], "last": "De Chaisemartin", "suffix": ""}, {"first": "V", "middle": [], "last": "Granger", "suffix": ""}], "year": 2019, "venue": "Anesthesiology", "volume": "130", "issn": "", "pages": "581--91", "other_ids": {}}, "BIBREF85": {"ref_id": "b85", "title": "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy", "authors": [{"first": "N", "middle": [], "last": "Tang", "suffix": ""}, {"first": "H", "middle": [], "last": "Bai", "suffix": ""}, {"first": "X", "middle": [], "last": "Chen", "suffix": ""}, {"first": "J", "middle": [], "last": "Gong", "suffix": ""}, {"first": "D", "middle": [], "last": "Li", "suffix": ""}, {"first": "Z", "middle": [], "last": "Sun", "suffix": ""}], "year": 2020, "venue": "J Thromb Haemost", "volume": "18", "issn": "", "pages": "1094--1103", "other_ids": {}}, "BIBREF86": {"ref_id": "b86", "title": "Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease", "authors": [{"first": "R", "middle": ["M"], "last": "Golonka", "suffix": ""}, {"first": "P", "middle": [], "last": "Saha", "suffix": ""}, {"first": "B", "middle": ["S"], "last": "Yeoh", "suffix": ""}], "year": 2020, "venue": "Physiol Genomics", "volume": "52", "issn": "", "pages": "217--238", "other_ids": {}}, "BIBREF87": {"ref_id": "b87", "title": "The architecture of SARS-CoV-2 transcriptome", "authors": [{"first": "K", "middle": [], "last": "Dongwan", "suffix": ""}, {"first": "L", "middle": [], "last": "Joo-Yeon", "suffix": ""}, {"first": "Y", "middle": [], "last": "Jeong-Sun", "suffix": ""}, {"first": "Jun", "middle": [], "last": "Won", "suffix": ""}, {"first": "K", "middle": [], "last": "", "suffix": ""}], "year": 2020, "venue": "Cell", "volume": "181", "issn": "", "pages": "", "other_ids": {}}, "BIBREF88": {"ref_id": "b88", "title": "Control of viral infections by epigenetic-targeted therapy", "authors": [{"first": "Z", "middle": [], "last": "Nehme", "suffix": ""}, {"first": "S", "middle": [], "last": "Pasquereau", "suffix": ""}, {"first": "G", "middle": [], "last": "Herbein", "suffix": ""}], "year": 2019, "venue": "Clin Epigenetics", "volume": "11", "issn": "", "pages": "", "other_ids": {}}, "BIBREF89": {"ref_id": "b89", "title": "Epigenetic mechanisms of importance for drug treatment", "authors": [{"first": "M", "middle": [], "last": "Ivanov", "suffix": ""}, {"first": "I", "middle": [], "last": "Barragan", "suffix": ""}, {"first": "M", "middle": [], "last": "Ingelman-Sundberg", "suffix": ""}], "year": 2014, "venue": "Trends Pharmacol Sci", "volume": "35", "issn": "", "pages": "384--96", "other_ids": {}}, "BIBREF90": {"ref_id": "b90", "title": "Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF-kB signaling pathway. Influenza Other Respir Virus", "authors": [{"first": "Y", "middle": [], "last": "Xu", "suffix": ""}, {"first": "L", "middle": [], "last": "Liu", "suffix": ""}], "year": 2017, "venue": "", "volume": "11", "issn": "", "pages": "457--63", "other_ids": {}}, "BIBREF91": {"ref_id": "b91", "title": "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing", "authors": [{"first": "D", "middle": ["E"], "last": "Gordon", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Jang", "suffix": ""}, {"first": "M", "middle": [], "last": "Bouhaddou", "suffix": ""}], "year": 2020, "venue": "Nature", "volume": "583", "issn": "", "pages": "459--68", "other_ids": {}}, "BIBREF92": {"ref_id": "b92", "title": "Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinicepolycytidylic acid-induced pneumonia", "authors": [{"first": "C", "middle": ["S"], "last": "Lee", "suffix": ""}, {"first": "E", "middle": ["H"], "last": "Yi", "suffix": ""}, {"first": "J", "middle": ["K"], "last": "Lee", "suffix": ""}], "year": 2013, "venue": "Eur Respir J", "volume": "41", "issn": "", "pages": "1147--56", "other_ids": {}}, "BIBREF93": {"ref_id": "b93", "title": "Statins may decrease the fatality rate of Middle East respiratory syndrome infection", "authors": [{"first": "S", "middle": [], "last": "Yuan", "suffix": ""}], "year": 2015, "venue": "mBio", "volume": "6", "issn": "", "pages": "1120--1135", "other_ids": {}}, "BIBREF94": {"ref_id": "b94", "title": "Metformin improves in vivo and in vitro B cell function in individuals with obesity and type-2 diabetes", "authors": [{"first": "A", "middle": [], "last": "Diaz", "suffix": ""}, {"first": "M", "middle": [], "last": "Romero", "suffix": ""}, {"first": "T", "middle": [], "last": "Vazquez", "suffix": ""}, {"first": "S", "middle": [], "last": "Lechner", "suffix": ""}, {"first": "B", "middle": ["B"], "last": "Blomberg", "suffix": ""}, {"first": "D", "middle": [], "last": "Frasca", "suffix": ""}], "year": 2017, "venue": "Vaccine", "volume": "35", "issn": "", "pages": "2694--700", "other_ids": {}}, "BIBREF95": {"ref_id": "b95", "title": "Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation", "authors": [{"first": "P", "middle": [], "last": "Ruiz-Lim On", "suffix": ""}, {"first": "R", "middle": [], "last": "Ortega", "suffix": ""}, {"first": "Arias", "middle": [], "last": "De La Rosa", "suffix": ""}, {"first": "I", "middle": [], "last": "", "suffix": ""}], "year": 2017, "venue": "Transl Res", "volume": "183", "issn": "", "pages": "87--103", "other_ids": {}}, "BIBREF96": {"ref_id": "b96", "title": "Interleukin-6 and tumour necrosis factor-a differentially regulate lincRNA transcripts in cells of the innate immune system in vivo in human subjects with rheumatoid arthritis", "authors": [{"first": "N", "middle": [], "last": "M\u00fc Ller", "suffix": ""}, {"first": "F", "middle": [], "last": "D\u20ac Oring", "suffix": ""}, {"first": "M", "middle": [], "last": "Klapper", "suffix": ""}], "year": 2014, "venue": "Cytokine", "volume": "68", "issn": "", "pages": "65--73", "other_ids": {}}, "BIBREF97": {"ref_id": "b97", "title": "Potential inhibitor of COVID-19 main protease (M pro ) from several medicinal plant compounds by molecular docking study", "authors": [{"first": "S", "middle": [], "last": "Khaerunnisa", "suffix": ""}, {"first": "H", "middle": [], "last": "Kurniawan", "suffix": ""}, {"first": "R", "middle": [], "last": "Awaluddin", "suffix": ""}, {"first": "S", "middle": [], "last": "Suhartati", "suffix": ""}, {"first": "S", "middle": [], "last": "Soetjipto", "suffix": ""}], "year": null, "venue": "", "volume": "2020", "issn": "", "pages": "", "other_ids": {"DOI": ["10.20944/preprints202003.0226.v1"]}}, "BIBREF98": {"ref_id": "b98", "title": "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", "authors": [{"first": "R", "middle": [], "last": "Yan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "L", "middle": [], "last": "Xia", "suffix": ""}, {"first": "Y", "middle": [], "last": "Guo", "suffix": ""}, {"first": "Q", "middle": [], "last": "Zhou", "suffix": ""}], "year": 2020, "venue": "Science", "volume": "367", "issn": "", "pages": "1444--1452", "other_ids": {}}, "BIBREF99": {"ref_id": "b99", "title": "Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients", "authors": [{"first": "C", "middle": [], "last": "Napoli", "suffix": ""}, {"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "C", "middle": [], "last": "Schiano", "suffix": ""}, {"first": "M", "middle": [], "last": "Salvatore", "suffix": ""}], "year": 2020, "venue": "Eur Heart J Cardiovasc Pharmacother", "volume": "6", "issn": "", "pages": "239--286", "other_ids": {}}, "BIBREF100": {"ref_id": "b100", "title": "Influence of statins on influenza vaccine response in elderly individuals", "authors": [{"first": "S", "middle": [], "last": "Black", "suffix": ""}, {"first": "U", "middle": [], "last": "Nicolay", "suffix": ""}, {"first": "Del", "middle": [], "last": "Giudice", "suffix": ""}, {"first": "G", "middle": [], "last": "Rappuoli", "suffix": ""}, {"first": "R", "middle": [], "last": "", "suffix": ""}], "year": 2016, "venue": "J Infect Dis", "volume": "213", "issn": "", "pages": "1224--1232", "other_ids": {}}, "BIBREF101": {"ref_id": "b101", "title": "Mechanisms of action and efficacy of statins against influenza", "authors": [{"first": "P", "middle": [], "last": "Mehrbod", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Omar", "suffix": ""}, {"first": "M", "middle": [], "last": "Hair-Bejo", "suffix": ""}, {"first": "A", "middle": [], "last": "Haghani", "suffix": ""}, {"first": "A", "middle": [], "last": "Ideris", "suffix": ""}], "year": 2014, "venue": "Biomed Res Int", "volume": "2014", "issn": "", "pages": "", "other_ids": {}}, "BIBREF102": {"ref_id": "b102", "title": "Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness", "authors": [{"first": "S", "middle": ["B"], "last": "Omer", "suffix": ""}, {"first": "V", "middle": ["K"], "last": "Phadke", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Bednarczyk", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Chamberlain", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Brosseau", "suffix": ""}, {"first": "W", "middle": ["A"], "last": "Orenstein", "suffix": ""}], "year": 2015, "venue": "J Infect Dis", "volume": "213", "issn": "", "pages": "1216--1239", "other_ids": {}}, "BIBREF103": {"ref_id": "b103", "title": "Effect of statin use on influenza vaccine effectiveness", "authors": [{"first": "H", "middle": ["Q"], "last": "Mclean", "suffix": ""}, {"first": "B", "middle": ["D"], "last": "Chow", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Vanwormer", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "King", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Belongia", "suffix": ""}], "year": 2016, "venue": "J Infect Dis", "volume": "214", "issn": "", "pages": "1150--1158", "other_ids": {}}, "BIBREF104": {"ref_id": "b104", "title": "Statin use and risks of influenza-related outcomes among older adults receiving standard-dose or high-dose influenza vaccines through Medicare during", "authors": [{"first": "H", "middle": ["S"], "last": "Izurieta", "suffix": ""}, {"first": "Y", "middle": [], "last": "Chillarige", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Kelman", "suffix": ""}], "year": 2018, "venue": "Clin Infect Dis", "volume": "67", "issn": "", "pages": "378--87", "other_ids": {}}, "BIBREF105": {"ref_id": "b105", "title": "Efficacy of high-dose versus standard-dose influenza vaccine in older adults", "authors": [{"first": "C", "middle": ["A"], "last": "Diazgranados", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Dunning", "suffix": ""}, {"first": "M", "middle": [], "last": "Kimmel", "suffix": ""}], "year": 2014, "venue": "N Engl J Med", "volume": "371", "issn": "", "pages": "635--680", "other_ids": {}}, "BIBREF106": {"ref_id": "b106", "title": "Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: openlabel, randomized study", "authors": [{"first": "D", "middle": [], "last": "Makris", "suffix": ""}, {"first": "E", "middle": [], "last": "Manoulakas", "suffix": ""}, {"first": "A", "middle": [], "last": "Komnos", "suffix": ""}], "year": 2011, "venue": "Crit Care Med", "volume": "39", "issn": "", "pages": "2440--2446", "other_ids": {}}, "BIBREF107": {"ref_id": "b107", "title": "Effect of statin treatment on short term mortality after pneumonia episode: cohort study", "authors": [{"first": "I", "middle": [], "last": "Douglas", "suffix": ""}, {"first": "S", "middle": [], "last": "Evans", "suffix": ""}, {"first": "L", "middle": [], "last": "Smeeth", "suffix": ""}], "year": 2011, "venue": "BMJ", "volume": "342", "issn": "", "pages": "", "other_ids": {}}, "BIBREF108": {"ref_id": "b108", "title": "Effect of statin therapy on mortality in patients with ventilatorassociated pneumonia: a randomized clinical trial", "authors": [{"first": "L", "middle": [], "last": "Papazian", "suffix": ""}, {"first": "A", "middle": [], "last": "Roch", "suffix": ""}, {"first": "P", "middle": ["E"], "last": "Charles", "suffix": ""}], "year": 2013, "venue": "JAMA", "volume": "310", "issn": "", "pages": "1692--700", "other_ids": {}}, "BIBREF109": {"ref_id": "b109", "title": "Epigenetic-sensitive challenges of cardio-hepatic interactions: clinical and therapeutic implications in heart failure patients", "authors": [{"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "O", "middle": [], "last": "Cuomo", "suffix": ""}, {"first": "M", "middle": [], "last": "Vasco", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF110": {"ref_id": "b110", "title": "Clinical features of COVID-19-related liver damage", "authors": [{"first": "Z", "middle": [], "last": "Fan", "suffix": ""}, {"first": "L", "middle": [], "last": "Chen", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Clin Gastroenterol Hepatol", "volume": "18", "issn": "", "pages": "1561--1567", "other_ids": {}}, "BIBREF111": {"ref_id": "b111", "title": "Liver injury during highly pathogenic human coronavirus infections", "authors": [{"first": "L", "middle": [], "last": "Xu", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "M", "middle": [], "last": "Lu", "suffix": ""}, {"first": "D", "middle": [], "last": "Yang", "suffix": ""}, {"first": "X", "middle": [], "last": "Zheng", "suffix": ""}], "year": 2020, "venue": "Liver Int", "volume": "40", "issn": "", "pages": "998--1004", "other_ids": {}}, "BIBREF112": {"ref_id": "b112", "title": "Effects of simvastatin on cell viability and proinflammatory pathways in lung adenocarcinoma cells exposed to hydrogen peroxide", "authors": [{"first": "L", "middle": [], "last": "Gallelli", "suffix": ""}, {"first": "D", "middle": [], "last": "Falcone", "suffix": ""}, {"first": "M", "middle": [], "last": "Scaramuzzino", "suffix": ""}], "year": 2014, "venue": "BMC Pharmacol Toxicol", "volume": "15", "issn": "", "pages": "", "other_ids": {}}, "BIBREF113": {"ref_id": "b113", "title": "Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway", "authors": [{"first": "X", "middle": [], "last": "Yuan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Deng", "suffix": ""}, {"first": "X", "middle": [], "last": "Guo", "suffix": ""}, {"first": "J", "middle": [], "last": "Shang", "suffix": ""}, {"first": "D", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "H", "middle": [], "last": "Liu", "suffix": ""}], "year": 2014, "venue": "Biochem Biophys Res Commun", "volume": "446", "issn": "", "pages": "292--299", "other_ids": {}}, "BIBREF114": {"ref_id": "b114", "title": "Metformin-induced suppression of IFN-a via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes", "authors": [{"first": "W", "middle": [], "last": "Saenwongsa", "suffix": ""}, {"first": "A", "middle": [], "last": "Nithichanon", "suffix": ""}, {"first": "M", "middle": [], "last": "Chittaganpitch", "suffix": ""}], "year": 2020, "venue": "Sci Rep", "volume": "10", "issn": "", "pages": "", "other_ids": {}}, "BIBREF115": {"ref_id": "b115", "title": "Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy", "authors": [{"first": "E", "middle": [], "last": "Lindmark", "suffix": ""}, {"first": "E", "middle": [], "last": "Diderholm", "suffix": ""}, {"first": "L", "middle": [], "last": "Wallentin", "suffix": ""}, {"first": "A", "middle": [], "last": "Siegbahn", "suffix": ""}], "year": 2001, "venue": "JAMA", "volume": "286", "issn": "", "pages": "2107--2120", "other_ids": {}}, "BIBREF116": {"ref_id": "b116", "title": "Coronavirus disease 2019 (COVID-19) and cardiovascular disease", "authors": [{"first": "K", "middle": ["J"], "last": "Clerkin", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Fried", "suffix": ""}, {"first": "J", "middle": [], "last": "Raikhelkar", "suffix": ""}], "year": 2020, "venue": "Circulation", "volume": "141", "issn": "", "pages": "1648--55", "other_ids": {}}, "BIBREF117": {"ref_id": "b117", "title": "Precision medicine in distinct heart failure phenotypes: focus on clinical epigenetics", "authors": [{"first": "C", "middle": [], "last": "Napoli", "suffix": ""}, {"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "F", "middle": [], "last": "Donatelli", "suffix": ""}, {"first": "Ambrosio", "middle": ["G"], "last": "", "suffix": ""}], "year": 2020, "venue": "Am Heart J", "volume": "224", "issn": "", "pages": "113--141", "other_ids": {}}, "BIBREF118": {"ref_id": "b118", "title": "New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?", "authors": [{"first": "C", "middle": ["A"], "last": "Devaux", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Rolain", "suffix": ""}, {"first": "P", "middle": [], "last": "Colson", "suffix": ""}, {"first": "D", "middle": [], "last": "Raoult", "suffix": ""}], "year": 2020, "venue": "Int J Antimicrob Agents", "volume": "55", "issn": "", "pages": "", "other_ids": {}}, "BIBREF119": {"ref_id": "b119", "title": "A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19", "authors": [{"first": "D", "middle": ["R"], "last": "Boulware", "suffix": ""}, {"first": "M", "middle": ["F"], "last": "Pullen", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Bangdiwala", "suffix": ""}], "year": 2020, "venue": "Advance Access", "volume": "383", "issn": "", "pages": "517--542", "other_ids": {"DOI": ["10.1056/NEJMoa2016638"]}}, "BIBREF120": {"ref_id": "b120", "title": "A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine", "authors": [{"first": "R", "middle": [], "last": "Catalano", "suffix": ""}, {"first": "R", "middle": [], "last": "Rocca", "suffix": ""}, {"first": "G", "middle": [], "last": "Juli", "suffix": ""}], "year": 2019, "venue": "Eur J Med Chem", "volume": "183", "issn": "", "pages": "", "other_ids": {}}, "BIBREF121": {"ref_id": "b121", "title": "Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents", "authors": [{"first": "S", "middle": [], "last": "Ayaz", "suffix": ""}, {"first": "F", "middle": [], "last": "Crea", "suffix": ""}], "year": 2020, "venue": "Epigenomics", "volume": "12", "issn": "", "pages": "811--813", "other_ids": {}}, "BIBREF122": {"ref_id": "b122", "title": "Inhibitors of the histone methyltransferases EZH2/1 induce a potent antiviral state and suppress infection by diverse viral pathogens", "authors": [{"first": "J", "middle": ["H"], "last": "Arbuckle", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Gardina", "suffix": ""}, {"first": "D", "middle": ["N"], "last": "Gordon", "suffix": ""}], "year": 2017, "venue": "", "volume": "8", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1128/mBio.01141-17"]}}, "BIBREF123": {"ref_id": "b123", "title": "Remdesivir for 5 or 10 days in patients with severe Covid-19", "authors": [{"first": "J", "middle": ["D"], "last": "Goldman", "suffix": ""}, {"first": "Dcb", "middle": [], "last": "Lye", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Hui", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1056/NEJMoa2015301"]}}, "BIBREF124": {"ref_id": "b124", "title": "Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome", "authors": [{"first": "A", "middle": [], "last": "Phrommintikul", "suffix": ""}, {"first": "S", "middle": [], "last": "Kuanprasert", "suffix": ""}, {"first": "W", "middle": [], "last": "Wongcharoen", "suffix": ""}, {"first": "R", "middle": [], "last": "Kanjanavanit", "suffix": ""}, {"first": "R", "middle": [], "last": "Chaiwarith", "suffix": ""}, {"first": "A", "middle": [], "last": "Sukonthasarn", "suffix": ""}], "year": 2011, "venue": "Eur Heart J", "volume": "32", "issn": "", "pages": "1730--1735", "other_ids": {}}, "BIBREF125": {"ref_id": "b125", "title": "Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A Review", "authors": [{"first": "C", "middle": [], "last": "Napoli", "suffix": ""}, {"first": "I", "middle": [], "last": "Tritto", "suffix": ""}, {"first": "G", "middle": [], "last": "Benincasa", "suffix": ""}, {"first": "G", "middle": [], "last": "Mansueto", "suffix": ""}, {"first": "Ambrosio", "middle": ["G"], "last": "", "suffix": ""}], "year": 2020, "venue": "Ann Med Surg (Lond)", "volume": "57", "issn": "", "pages": "236--279", "other_ids": {}}, "BIBREF126": {"ref_id": "b126", "title": "Can COVID 2019 disease induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?", "authors": [{"first": "G", "middle": [], "last": "Mansueto", "suffix": ""}, {"first": "M", "middle": [], "last": "Niola", "suffix": ""}, {"first": "C", "middle": [], "last": "Napoli", "suffix": ""}], "year": 2020, "venue": "Pathol Res Pract", "volume": "216", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.prp.2020.153086"]}}, "BIBREF127": {"ref_id": "b127", "title": "COVID-19: do not be phobic from fever", "authors": [{"first": "M", "middle": [], "last": "Galdiero", "suffix": ""}, {"first": "C", "middle": [], "last": "Napoli", "suffix": ""}], "year": 2020, "venue": "J Infect Public Health", "volume": "13", "issn": "", "pages": "", "other_ids": {}}, "BIBREF128": {"ref_id": "b128", "title": "Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2", "authors": [{"first": "Y", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hou", "suffix": ""}, {"first": "J", "middle": [], "last": "Shen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Huang", "suffix": ""}, {"first": "W", "middle": [], "last": "Martin", "suffix": ""}, {"first": "F", "middle": [], "last": "Cheng", "suffix": ""}], "year": 2020, "venue": "Cell Discov", "volume": "6", "issn": "", "pages": "", "other_ids": {}}, "BIBREF129": {"ref_id": "b129", "title": "Molecular networks in network medicine: development and applications", "authors": [{"first": "E", "middle": ["K"], "last": "Silverman", "suffix": ""}, {"first": "Hhh", "middle": [], "last": "Schmidt", "suffix": ""}, {"first": "E", "middle": [], "last": "Anastasiadou", "suffix": ""}], "year": null, "venue": "Wiley Interdiscip Rev Syst Biol Med", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "with DNA virus, a few reports provided proofs of v-miRNAs originating from RNA virus. Varble and colleagues79 incorporated a hairpin miRNA-124 into the influenza virus genome showing that the engineered virus was able to produce a functional miR-124 without any harmful consequence on the viral life cycle. This suggested that RNA viruses may also exploit the host nuclear RNA machinery to synthesise v-miRNAs, which might contribute to the typical influenza-virus-induced cytokine storm. Successively, Umbach and colleagues 80 demonstrated that the 5 0 end of all the eight segments of the influenza virus can codify for small viral leader RNAs, which are involved in the genomic RNA encapsidation to provide a new progeny of virions, suggesting a relevant role in the viral life cycle. Li and colleagues76 have demonstrated that H5N1 virus encodes miR-HA-3p, a miRNA-like small RNA exacerbating the production of antiviral cytokines by downregulating the poly(RC)binding protein 2 gene, a master regulator of the retinoic acid-inducible gene-I (RIG)/mitochondrial antiviral signalling protein (MAVS) antiviral signalling, in human macrophages. This proved a novel virulence factor underlying H5N1-Viralehost epigenetic interactions. We illustrated three putative cell-specific epigenetic-sensitive mechanisms by which SARS-CoV-2 and H5N1 may impact on individual sensitiveness to severe pulmonary critical illness. Mainly, T cells and neutrophils can undergo deoxyribonucleic acid hypomethylation and histone modifications, respectively, in COVID-19 patients. Otherwise, in vitro lung epithelial cells upon H5N1 infection can undergo modifications of micro-ribonucleic acid (RNA) patterns and histone tail marks, leading to downregulation of antiviral defence (see the text for more details). ACE, angiotensin-converting enzyme; AGO2, argonaute 2; CGI, CpG island; COVID-19, coronavirus disease 2019; mRNA, messenger RNA; NET, neutrophil extracellular trap; NS1, non-structural protein 1; PCBP2, poly(RC)-binding protein 2; ROS, reactive oxygen species; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SLE, systemic lupus erythematosus.", "latex": null, "type": "figure"}, "TABREF1": {"text": "Clinical and immunological features of viral respiratory infections by highly pathogenic coronaviruses. 47e60 ARDS, acute respiratory distress syndrome; BOOP, bronchiolitis obliterans organising pneumonia; CT, computed tomography; HF, heart failure; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Clinical signs and\nsymptoms\n</td><td>Transmissibility and\nmortality rate\n</td><td>Lung pathological\nfeatures\n</td><td>Immunological features </td><td>Radiographic\nfindings\n</td></tr><tr><td>Early stage: moderate\ndisease with flu-like\nsymptoms\nAdvanced stage: ARDS,\nseptic shock, acute\nkidney injury, HF,\ncoagulation dysfunction,\nand death (mainly in\nolder patients)\n</td><td>SARS-CoV-2 shows a\nhigher transmissibility\nrate with respect to\nSARS-CoV and MERS-\n</td><td>Early stage: diffuse\nalveolar damage\n(necrosis of alveolar\nepithelial cells, hyaline\nmembrane formation,\ninfiltration with\ninflammatory cells, and\npresence of giant\nmultinucleated cells)\n</td><td>Initiation phase: antiviral\ninnate immunity in the\nlung\nResolution phase: viral\nclearance and the\nprocess\nRestoration phase: repair\nprocesses associated\nwith viral respiratory\ntract infections\n</td><td>Chest CT shows\nbilateral ground\nglass opacities\nand\nsubsegmental\nareas of\nconsolidation\n</td></tr><tr><td>CoV\n</td></tr><tr><td>MERS-CoV shows a\nmortality rate higher\nthan SARS-CoV and\n</td><td>\u00a0</td></tr><tr><td>SARS-CoV-2\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Proliferative phase:\nhyperplasia of Type II\npneumocytes (with\nmild-to-moderate\nfibrosis and a BOOP\npattern)\n</td><td>\u00a0</td><td>\u00a0</td></tr></table></body></html>"}, "TABREF2": {"text": "Major epigenetic mechanisms during viral respiratory infections. ACE2, angiotensin-converting enzyme 2; CFHR1, complement factor H-related 1; DDX58, DExD/H-box helicase 58; NET, neutrophil extracellular trap; PCBP2, poly(RC) binding protein 2; SAMD9L, sterile alpha motif domain-containing protein 9-like; v-miRNA, viral micro-ribonucleic acid.Human macrophages miR-HA-3p (v-miRNA)", "latex": null, "type": "table"}, "TABREF3": {"text": "Epidrugs and repurposed drugs in viral respiratory infections.", "latex": null, "type": "table"}, "TABREF4": {"text": "Novel and repurposed drugs modulating epigenetic pathways in clinical trials to treat viral pulmonary infections.", "latex": null, "type": "table"}, "TABREF5": {"text": "", "latex": null, "type": "table"}, "TABREF6": {"text": "", "latex": null, "type": "table"}, "TABREF7": {"text": "Continued Epidrug", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>randomised, doublind, placebo-\ncontrolled, multicstudy to evaluate the\n</td><td>(v) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>nterventional</td><td>describe the toxicity otocilizumab\no evaluate the efficacysafety,\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>pharmacokinetics, and\npharmacodynamics of\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>safety and effic</td><td>TCZ compared with\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>tocilizumab in patients\nwith severe COVID-19\npneumonia\n</td><td>placebo in combination\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>with SOC for the\ntreatment of severe\nCOVID-</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>randomised, coopen-label, </td><td>o assess the efficacydas\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>deter</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>proportion of patients\nwith nSpO2 96%dof constandard care together\nwith tocilizupembrolizumab 3475) in patients with\nCOVID-19 pneumonia\nwho are nonto front-line therapy\nwithin treatment initiation\no investigate the effect </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>ffectiveness of\ninterleukin-6 receptor\ninhibitors in the\n</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>different types of IL-inhibition vs no adjuvantreatment compa</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>management of patien</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr></table></body></html>"}}, "back_matter": [{"text": "This research was supported (in whole or in part) by Hospital Corporation of America (HCA) or HCA affiliated entity. The views expressed in this publication represent those of the authors and do not necessarily represent the official views of HCA or any of its affiliated entities.", "cite_spans": [], "ref_spans": [], "section": "Acknowledgements"}, {"text": "Design/implementation of the review: EC, GB, CN Critical feedback: NF-M, MG Writing of paper: all authors", "cite_spans": [], "ref_spans": [], "section": "Authors' contributions"}, {"text": "The authors declare that they have no conflicts of interest. ", "cite_spans": [], "ref_spans": [], "section": "Declarations of interest"}]}